| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-04-02 | MDxHealth (Belgium) LI PATH (USA - NY) | ConfirmMDx® for Prostate Cancer | prostate cancer | marketing |
Cancer - Oncology | Commercialisation agreement |
| 2014-04-02 | BioAlliance Pharma (France) Daewoong Pharmaceutical (South Korea) | Sitavig®/Sitavir® (Acyclovir Lauriad®) | recurrent labial herpes | licensing |
Infectious diseases | Licensing agreement |
| 2014-04-01 | Bioalliance Pharma (France) Vestiq Pharmaceuticals (USA) | Oravig® (miconazole Lauriad™ - Loramyc® in Europe) | oropharyngeal candidiasis | licensing |
Infectious diseases | Licensing agreement |
| 2014-04-01 | Merck Serono (Germany) Pfizer (USA - NY) Broad Institute (USA) | Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) biomarkers | systemic lupus erythematosus, lupus nephritis | R&D |
Autoimmune diseases | R&D agreement |
| 2014-04-01 | InDex Pharmaceuticals (Sweden) Almirall (Spain) | Kappaproct® | licensing |
Licensing agreement | ||
| 2014-04-01 | Fairjourney Biologics (Portugal) Biorap Technologies (Israel) Hadasit Medical Research Services and Development (Israel) | therapeutic antibodies that modulate Heparanase | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-03-31 | AstraZeneca (UK) Medical Research Council (UK) | R&D |
Establishment of a new subsidiary in the EU | |||
| 2014-03-31 | Evotec (Germany) Convergence Pharmaceuticals (UK) | compounds against a novel GPCR pain target | pain | R&D |
CNS diseases | R&D agreement |
| 2014-03-31 | Lundbeck (Denmark) Astellas (Japan) Pfizer (USA - NY) Roche (Switzerland) Eli Lilly (USA - IN) Lieber Institute for Brain Development (USA - MD) | R&D |
CNS diseases | R&D agreement | ||
| 2014-03-31 | BioAlliance Pharma (France) Penn Pharma (UK) | Validive® (clonidine Lauriad®) | severe oral mucositis induced by radiotherapy and/or chemotherapy in head and neck cancer patients | production |
Cancer - Oncology | Production agreement |
| 2014-03-31 | Clinigen (UK) SpePharm (The Netherlands), affiliate of Norgine (The Netherlands) | Savene® (dexrazoxane) | extravasation in anthracycline chemotherapy in adults | Cancer - Oncology | Product acquisition | |
| 2014-03-28 | Wilex (Germany) Link Health (China) | Mesupron® (upamostat) | HER2-negative metastatic breast cancer, non-metastatic pancreatic cancer | development licensing |
Cancer - Oncology | Licensing agreement |
| 2014-03-27 | Genmab (Denmark) MAB Discovery (Germany) | antibodies | R&D |
Technology - Services | R&D agreement | |
| 2014-03-27 | Medesis Pharma (France - Canada) CEA (France) | compounds designed to remove radioactive/toxic metal contaminants from the body | R&D |
Technology - Services | R&D agreement | |
| 2014-03-27 | HRA Pharma (France) Afaxys Pharmaceuticals (USA - SC) | ella® (ulipristal acetate - UPA) | emergency contraception | commercialisation |
Gynecology - Women\'s health | Commercialisation agreement |
| 2014-03-26 | Genentech, a member of the Roche Group (USA - Switzerland) Xenon Pharmaceuticals (Canada) | pain | CNS diseases | Collaboration agreement | ||
| 2014-03-25 | NeuroVive Pharmaceutical (Sweden) A1M Pharma (Sweden) | mitochondrial medicine | R&D | |||
| 2014-03-20 | Agency for Science, Technology and Research (A*STAR) (Singapore) Nutricia Research (The Netherlands) | microbiome | R&D |
Digestive diseases | R&D agreement | |
| 2014-03-19 | Sanofi Pasteur (France) SK Chemical (South Korea) | pneumococcal conjugate vaccine | pneumococcal infections | R&D |
Infectious diseases | R&D agreement |
| 2014-03-19 | BioAlliance Pharma (France) Innocutis (USA - SC) | Sitavig® (US)/Sitavir® (EU) (acyclovir Lauriad®) | herpes labialis | licensing |
Infectious diseases | Milestone |
